Benzylpiperazine: A drug of abuse?

Journal of Psychopharmacology

Volumn 21, Issue 8, 2007, Pages 888-894

  Johnstone, Alice C ^a,b   Lea, Rod A ^a   Brennan, Katie A ^c   Schenk, Susan ^c   Kennedy, Martin A ^b   Fitzmaurice, Paul S ^a,d  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d MT ALBERT RESEARCH CENTRE   (New Zealand)

Author keywords

Benzylpiperazine; BZP; Drugs of abuse; p.e.p. pills; Party pills; TFMPP

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; N BENZYLPIPERAZINE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG ABUSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BEHAVIOR, ANIMAL; DRUG AND NARCOTIC CONTROL; HUMANS; PIPERAZINES; STREET DRUGS;

EID: 35648979085     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107077260     Document Type: Review

References (56)

1. Aitchison L.K., Hughes R.N. (2006) Treatment of adolescent rats with 1-benzylpiperazine: a preliminary study of subsequent behavioral effects. Neurotoxicol Teratol 28: 453 - 458
2. Alansari M., Hamilton D. (2006) Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J 119: U1959
3. Auerbach S.B., Rutter J.J., Juliano P.J. (1991) Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology 30: 307 - 311
4. Austin H., Monasterio E. (2004) Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry 12: 406 - 408
5. Balmelli C., Kupferschmidt H., Rentsch K., Schneemann M. (2001) [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch Med Wochenschr 126: 809 - 811
6. Baumann M.H., Ayestas M.A., Sharpe L.G., Lewis D.B., Rice K.C., Rothman R.B. (2002) Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. 301: 1190 - 1197
7. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., Rothman R.B. (2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy') Neuropsychopharmacology 30: 550 - 560
8. Bilsky E.J., Reid L.D. (1991) MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav 39: 509
9. Bogatcheva E., Hanrahan C., Nikonenko B., Samala R., Chen P., Gearhart J., Barbosa F., Einck L., Nacy C.A., Protopopova M. (2006) Identification of New Diamine Scaffolds with Activity against Mycobacterium tuberculosis. J Med Chem 49: 3045 - 3048
10. Brennan K.A., Johnstone A.C., Fitzmaurice P.S., Lea R.A., Schenk S. (In press) Chronic benzylpiperazine (BZP) exposure produces behavioural sensitisation and cross sensitisation to methamphetamine (MA). Drug Alcohol Depend
11. Bye C., Munro-Faure A.D., Peck A.W., Young P.A. (1973) A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 6: 163 - 169
12. Campbell H., Cline W., Evans M., Lloyd J., Peck A.W. (1973) Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 6: 170 - 176
13. Cunningham K.A., Appel J.B. (1986) Possible 5-hydroxytryptamine1 (5-HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl) piperazine (TFMPP). J Pharmacol Exp Ther 237: 369 - 377
14. de Boer D., Bosman I.J., Hidvegi E., Manzoni C., Benko A.A., dos Reys L.J., Maes R.A. (2001) Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 121: 47 - 56
15. Dea (2004) Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Fed Regist 69: 12794 - 12797
16. Eacd. (April 2004). The Expert Advisory Committee on Drugs (EACD) Advice To The Minister On: Benzylpiperazine (BZP). National Drug Policy. Ref No: 20045663
17. Fantegrossi W.E., Winger G., Woods J.H., Woolverton W.L., Coop A. (2005) Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77: 161 - 168
18. Fergusson D.M., Boden J.M., Horwood L.J. (2006) Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101: 556 - 569
19. Fonyo M., Guttmann A., Magyar K. (1987) Species differences in the in vitro metabolism of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 39: 129 - 134
20. Gee P., Richardson S., Woltersdorf W., Moore G. (2005) Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 118: U1784
21. Glennon R.A., McKenney J.D., Young R. (1984) Discriminative stimulus properties of the serotonin agonist 1-(3-trifluoromethylphenyl)piperazine (TFMPP). Life Sci 35: 1475 - 1480
22. Guttmann A., Nagy J., Magyar K. (1987) The metabolism of EGYT-475, a new antidepressant agent, in rats. Pol J Pharmacol Pharm 39: 123 - 128
23. Herndon J.L., Pierson M.E., Glennon R.A. (1992) Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol Biochem Behav 43: 739 - 748
24. Hoyer D. (1988) Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8: 59 - 81
25. Kandel D., Yamaguchi K., Chen K. (1992) Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol 53: 447 - 457
26. Kosoczky I., Grasser K., Kiszelly E., Toncsev E., Petocz L. (1978) The antidepressant activity of a new piridin-carbonic acid derivative, EGYT-475. Abstract No 486. In: 7th International Congress of Pharmacology. Pergamon Press, Paris
27. Kreth K-P., Kovar K-A., Schwab M., Zanger U.M. (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59: 1563
28. Lemoucheux L., Rouden J., Ibazizene M., Sobrio F., Lasne M.C. (2003) Debenzylation of tertiary amines using phosgene or triphosgene: an efficient and rapid procedure for the preparation of carbamoyl chlorides and unsymmetrical ureas. Application in carbon-11 chemistry. J Org Chem 68: 7289 - 7297
29. Magyar K., Fekete M.I., Tekes K., Torok T.L. (1986) The action of trelibet, a new antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 130: 219 - 227
30. Magyar K. (1987) Pharmacokinetic aspects of the mode of action of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 39: 107 - 112
31. Malomvolgyi B., Tothfalusi L., Tekes K., Magyar K. (1991) Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent Trelibet (EGYT-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung 78: 201 - 209
32. Maurer H.H., Kraemer T., Springer D., Staack R.F. (2004) Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy). piperazine, and pyrrolidinophenone types: a synopsis. 26: 127 - 131
33. Meririnne E., Kajos M., Kankaanpaa A., Seppala T. (2006) Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 98: 346 - 350
34. Mhra 2006. pep pill seizure. http://www.mhra.gov.uk/home/idcplg? IdcService=GET_FILE&dDocName=CON2024548&RevisionSelectionMethod= LatestReleasedAccessed:01/11/2006
35. Ministerial Action Group on Drugs (2003) Methamphetamine Action Plan http://www.ndp.govt.nz/publications/methamphetamineactionplan.html
36. Murphy D.L., Lesch K.P., Aulakh C.S., Pigott T.A. (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 43: 527 - 552
37. Ndpsc (2006) National Drugs and Poisons Schedule Committee Department of Health and Ageing Therapeutic Goods Administration 46th Meeting http://www.tga.gov.au/ndpsc/record/rr200602.pdf
38. Nicholson T.C. (2006) Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department 18: 180 - 184
39. Oberlander C., Euvrard C., Dumont C., Boissier J.R. (1979) Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway. 60: 163 - 170
40. Peters F.T., Schaefer S., Staack R.F., Kraemer T., Maurer H.H. (2003) Screening for and validated quantification of amphetamines and of amphetamine-and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 38: 659 - 676
41. Pettibone D.J., Williams M. (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33: 1531 - 1535
42. Rotzinger S., Fang J., Coutts R.T., Baker G.B. (1998) Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 44: 1185 - 1191
43. Schechter M.D. (1988) Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Biochem Behav 31: 817 - 824
44. Schenk S., Izenwasser S. (2002) Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine 72: 651 - 657
45. Staack R.F., Fritschi G., Maurer H.H. (2002) Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 773: 35 - 46
46. Staack R.F., Paul L.D., Springer D., Kraemer T., Maurer H.H. (2004 a) Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 67: 235 - 244
47. Staack R.F., Theobald D.S., Paul L.D., Springer D., Kraemer T., Maurer H.H. (2004 b) In vivo metabolism of the new designer drug 1-(4-methoxyphenyl) piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 34: 179 - 192
48. Staack R.F., Maurer H.H. (2005) Metabolism of designer drugs of abuse. Curr Drug Metab 6: 259 - 274
49. Stanz (2005) Submission of Social Tonics Association of New Zealand to the Health Select Committee on the matter of Misuse of Drugs Amendment Bill (No 3) and the Supplementary Order Paper http://www.stanz.org.nz/ SOP%20Submission%20for%20STANZ%20%20-%20Jan%2020052.pdf
50. Szucks Z., Szentendrei T., Fekete M.I. (1987) The effect of EGYT-475 (Trelibet) and its metabolites on the potassium-stimulated 3H-noradrenaline release from cortical slices of rat brain. Pol J Pharmacol Pharm 39: 185 - 193
51. Tekes K., Tothfalusi L., Malomvolgyi B., Herman F., Magyar K. (1987) Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 39: 203 - 211
52. Tsutsumi H., Katagi M., Miki A., Shima N., Kamata T., Nishikawa M., Nakajima K., Tsuchihashi H. (2005) Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP). 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J Chromatogr B Analyt Technol Biomed Life Sci 819: 315 - 322
53. Tsutsumi H., Katagi M., Miki A., Shima N., Kamata T., Nakajima K., Inoue H., Kishi T., Tsuchihashi H. (2006) Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol 30: 38 - 43
54. Vollenweider F.X., Gamma A., Liechti M., Huber T. (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241 - 251
55. Wikstrom M., Holmgren P., Ahlner J. (2004) A2 (N-benzylpiperazine) a new drug of abuse in Sweden 28: 67 - 70
56. Wilkins C., Girling M., Sweetsur P., Huckle T., Huakau J. (2006). Legal party pill use in New Zealand: Prevalence of use, availability, health harms and 'gateway effects' of benzylpiperzine (BZP) and triflourophenylmethylpiperazine (TFMPP) [sic]. Centre for Social and Health Outcomes Research and Evaluation (SHORE). Massey University, Auckland, New Zealand